Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24;46(5):298-303.
doi: 10.1080/01658107.2022.2047207. eCollection 2022.

A Protective Role of Coenzyme Q10 in Ethambutol-Induced Retinal Ganglion Cell Toxicity: A Randomised Controlled Trial in Mice

Affiliations

A Protective Role of Coenzyme Q10 in Ethambutol-Induced Retinal Ganglion Cell Toxicity: A Randomised Controlled Trial in Mice

Josiah Irma et al. Neuroophthalmology. .

Abstract

Ethambutol is a widely used drug to treat tuberculosis that may cause visual disturbance including ethambutol toxic optic neuropathy (ETON). The disease disrupts bodily tissues' energy production, including the retinal ganglion cells (RGC). Many have proposed treatment with coenzyme Q10 (coQ10) due to its antioxidant and facilitative effects that can improve mitochondrial electron transport. The present study hence assessed whether coQ10 could protect against ETON through a parallel triple-blinded randomised controlled trial in 18 mice using computer-generated tables for treatment allocation. All of the mice received 25 mg/kg ethambutol daily, while only nine in the treated group also received 100 mg/kg coQ10. After 30 days, blinded pathologists counted RGC numbers in enucleated and dyed orbital tissue. The treated group had significantly denser RGCs at 47.2 (standard deviation [SD] 10.6) cells per 500 µm microscope field vs 33.5 (SD 6.3) in the control group (t = 3.34, p = .004). CoQ10 therefore protected RGCs from ETON. Clinical trials of coQ10 in human subjects treated with ethambutol should be considered.

Keywords: Ethambutol; coenzyme Q10; ethambutol toxic optic neuropathy; retinal ganglion cells; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Tissue and paraffin preparation.
Figure 2.
Figure 2.
Haematoxylin and eosin staining techniques.
Figure 3.
Figure 3.
Haematoxylin and eosin stained histological Appearance (400 x) of retinal ganglion cells in ethambutol treated mice with (a) and without (b) coenzyme Q10 supplementation.

References

    1. Centers for Disease Control and Prevention (CDC) . CDC at the Forefront of Innovation in the Global Fight against TB. USA: CDC; 2021.
    1. Alisjahbana B, Koesoemadinata RC, Hadisoemarto PF, et al. Are neighbourhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case finding. Hasnain SE, ed. PLoS One. 2021;16(8):e0256043.doi:10.1371/journal.pone.0256043. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention (CDC) . CDC in Indonesia. 2021. https://www.cdc.gov/globalhealth/countries/indonesia/pdf/indonesia-fs.pdf. Accessed December 5, 2021.
    1. Kementerian Kesehatan Republik Indonesia . Situasi Tuberkulosis Indonesia Tahun 2020. Indonesia: Indonesian Ministry of Health; 2021.
    1. Arya V. A review on anti-tubercular plants. Int J PharmTech Res. 2011; 3(2):872–880.

LinkOut - more resources